Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.
So far, no pediatric doses for indinavir combined with ritonavir have been defined. This study evaluated the pharmacokinetics of 400 mg of indinavir/m(2) combined with 125 mg of ritonavir/m(2) every 12 h (q12h) in 14 human immunodeficiency virus type 1-infected children. The area under the concentration-time curve from 0 to 24 h and the minimum concentration of drug in serum for indinavir were similar to those for 800 mg of indinavir-100 mg of ritonavir q12h in adults, while the maximum concentration of drug in serum was slightly decreased, with geometric mean ratios (90% confidence intervals in parentheses) of 1.1 (0.87 to 1.3), 0.96 (0.60 to 1.5), and 0.80 (0.68 to 0.94), respectively.
Bergshoeff
A S
AS
University Medical Center, Department of Clinical Pharmacy, Nijmegen University Center for Infectious Diseases, Nijmegen, The Netherlands.
Fraaij
P L A
PL
van Rossum
A M C
AM
Verweel
G
G
Wynne
L H
LH
Winchell
G A
GA
Leavitt
R Y
RY
Nguyen
B-Y T
BY
de Groot
R
R
Burger
D M
DM
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000378:metabolism*; D015497:HIV-1; D006801:Humans; D019469:Indinavir / Q000009:adverse effects / Q000493:pharmacokinetics*; D008297:Male; D011446:Prospective Studies; D019438:Ritonavir / Q000009:adverse effects / Q000493:pharmacokinetics*
D019380:Anti-HIV Agents; D004338:Drug Combinations; D019469:Indinavir; D019438:Ritonavir